Phreesia (NYSE:PHR) Insider Yvonne Hui Sells 940 Shares

Key Points

• Yvonne Hui, an insider at Phreesia, sold 940 shares at an average price of $23.28, which decreased her position by 2.98%, leaving her with a total of 30,638 shares valued at approximately $713,252.64.
• Phreesia's stock recently traded up to $24.28 and has experienced a 52-week range with a low of $17.07 and a high of $32.76.
• Analysts have issued price targets for Phreesia, with estimates ranging from $32.00 to $36.00, suggesting a generally optimistic outlook on the company’s performance.

Phreesia, Inc. (NYSE:PHR - Get Free Report) insider Yvonne Hui sold 940 shares of Phreesia stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total value of $21,883.20. Following the completion of the sale, the insider directly owned 30,638 shares in the company, valued at approximately $713,252.64. This represents a 2.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Yvonne Hui also recently made the following trade(s):

• On Friday, July 18th, Yvonne Hui sold 626 shares of Phreesia stock. The stock was sold at an average price of $26.23, for a total transaction of $16,419.98.
• On Thursday, July 17th, Yvonne Hui sold 465 shares of Phreesia stock. The shares were sold at an average price of $26.89, for a total value of $12,503.85.
• On Wednesday, July 16th, Yvonne Hui sold 422 shares of Phreesia stock. The stock was sold at an average price of $26.95, for a total value of $11,372.90.
• On Tuesday, July 15th, Yvonne Hui sold 307 shares of Phreesia stock. The stock was sold at an average price of $27.27, for a total value of $8,371.89.
• On Monday, July 7th, Yvonne Hui sold 571 shares of Phreesia stock. The shares were sold at an average price of $28.85, for a total value of $16,473.35.

Phreesia Stock Performance

Shares of NYSE:PHR traded up $1.00 during trading on Thursday, hitting $24.28. 801,987 shares of the company were exchanged, compared to its average volume of 1,182,744. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $32.76. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average price of $27.71 and a two-hundred day moving average price of $26.40.

Phreesia (NYSE:PHR - Get Free Report) last released its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The business had revenue of $117.26 million during the quarter, compared to analysts' expectations of $116.39 million. During the same period last year, the business earned ($0.03) earnings per share. The firm's revenue was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. On average, research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on PHR shares. Raymond James Financial set a $33.00 price objective on Phreesia and gave the company an "outperform" rating in a research note on Friday, September 5th. Stephens reaffirmed an "overweight" rating and set a $32.00 price target on shares of Phreesia in a report on Wednesday, September 3rd. Piper Sandler lifted their price objective on shares of Phreesia from $33.00 to $34.00 and gave the stock an "overweight" rating in a research report on Friday, September 5th. Truist Financial increased their price objective on shares of Phreesia from $35.00 to $36.00 and gave the company a "buy" rating in a research report on Friday, September 5th. Finally, JMP Securities lifted their target price on shares of Phreesia from $30.00 to $34.00 and gave the stock a "market outperform" rating in a report on Monday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating and twelve have given a Buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $34.08.

Institutional Trading of Phreesia

A number of institutional investors have recently bought and sold shares of PHR. KBC Group NV acquired a new position in shares of Phreesia during the 1st quarter worth approximately $74,000. Farther Finance Advisors LLC boosted its stake in shares of Phreesia by 9,375.0% in the second quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company's stock valued at $86,000 after buying an additional 3,000 shares during the period. CWM LLC grew its position in Phreesia by 994.9% during the first quarter. CWM LLC now owns 4,040 shares of the company's stock worth $103,000 after buying an additional 3,671 shares in the last quarter. Smartleaf Asset Management LLC grew its position in Phreesia by 53.0% during the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock worth $137,000 after buying an additional 1,825 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Phreesia by 332.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,610 shares of the company's stock worth $160,000 after acquiring an additional 4,313 shares during the period. Institutional investors own 92.10% of the company's stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.